A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+metastatic breast cancer (MBC)

被引：0
|
作者：
Borges, Virginia F. [1 ]
Hamilton, Erika [2 ,3 ]
Yardley, Denise A. [2 ,3 ]
Chaves, Jorge [4 ]
Aucoin, Nathalie [5 ]
Ferrario, Cristiano [6 ]
Walker, Luke [7 ]
Krop, Ian [8 ]
机构：
[1] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Tennessee Oncol PLLC, Nashville, TN USA
[4] Northwest Med Specialties, Tacoma, WA USA
[5] Hop Cite de la Sante, Laval, PQ, Canada
[6] Jewish Gen Hosp, Montreal, PQ, Canada
[7] Oncothyreon Inc, Seattle, WA USA
[8] Dana Farber Canc Inst, Boston, MA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-15-08
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [32] Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis
    Dhamne, Nilesh
    Koyyala, Venkata Pradeep Babu
    Chougule, Snehal
    Pawar, Suraj
    BMJ CASE REPORTS, 2022, 15 (05)
  • [33] Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice
    Ferraro, Gino B.
    Askoxylakis, Vasileios
    Kodack, David P.
    Badeaux, Mark
    Fukumura, Dai
    Engelman, Jeffrey A.
    Jain, Rakesh K.
    CANCER RESEARCH, 2016, 76
  • [34] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
    Cortes, J.
    Kim, S-B.
    Chung, W-P.
    Im, S-A.
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L-M.
    Petry, V.
    Chung, C-F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
  • [35] A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)
    Dumbrava, Ecaterina E.
    Kennon, Amber M.
    Murthy, Rashmi K.
    Montazari, Emma J.
    Tawbi, Hussein
    Li, Jing
    Lang, Frederick F.
    Sanchez, Gisela
    Wang, Jianbo
    Glitza, Isabella C.
    O'Brien, Barbara J.
    Beckham, Thomas
    Swanson, Todd
    Tom, Martin C.
    Vu, Uyen M.
    Darko, Tanisha T.
    Cai, Tiantian
    Shah, Komal
    Meric-Bernstam, Funda
    Rodon, Jordi
    CANCER RESEARCH, 2024, 84 (07)
  • [36] A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): Final results
    Vogel, C. L.
    Burris, H. A.
    Limentani, S.
    Borson, R.
    O'Shaughnessy, J.
    Vukelja, S.
    Agresta, S.
    Klencke, B.
    Birkner, M.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
    Peddi, Parvin F.
    Hurvitz, Sara A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (05) : 202 - 209
  • [38] Potential life years sawed using ado-trastuzumab emtansine (T-DM1) in second-line HER2-positive metastatic breast cancer.
    Danese, Mark D.
    Halperin, Marc
    Masaquel, Anthony
    Abidoye, Oyewale O.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study
    Yardley, Denise Aysel
    Krop, Ian E.
    LoRusso, Patricia
    Robert, Nicholas J.
    Mayer, Musa
    Abidoye, Oyewale O.
    Lai, Catherine
    Yoo, Bongin
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [40] NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
    Jacobs, Samuel A.
    Wang, Ying
    Abraham, Jame
    Feng, Huichen
    Montero, Alberto J.
    Lipchik, Corey
    Finnigan, Melanie
    Jankowitz, Rachel C.
    Salkeni, Mohamad A.
    Maley, Sai K.
    Puhalla, Shannon L.
    Piette, Fanny
    Quinn, Katie
    Chang, Kyle
    Nagy, Rebecca J.
    Allegra, Carmen J.
    Vehec, Kelly
    Wolmark, Norman
    Lucas, Peter C.
    Srinivasan, Ashok
    Pogue-Geile, Katherine L.
    BREAST CANCER RESEARCH, 2024, 26 (01)
12345